Vera Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Vera Therapeutics, Inc., a biotechnology company, filed this Form 8-K regarding its 2022 Annual Meeting of Stockholders held on May 24, 2022. The filing was signed on May 25, 2022. As of the March 29, 2022 record date, 26,756,235 shares of Class A common stock were outstanding and entitled to vote.
Meeting results and key corporate matters
| Proposal | Result |
|---|
| Election of Class I directors | Marshall Fordyce, M.D.; Beth Seidenberg, M.D.; and Kimball Hall were elected to serve until the 2025 Annual Meeting and until their successors are qualified. |
| Ratification of independent auditor | Stockholders ratified the Audit Committee’s selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022. |
Voting results
| Director | Votes for | Votes withheld | Broker non-votes |
|---|
| Marshall Fordyce, M.D. | 19,200,935 | 310,631 | 2,929,530 |
| Beth Seidenberg, M.D. | 19,193,043 | 318,523 | 2,929,530 |
| Kimball Hall | 19,504,996 | 6,570 | 2,929,530 |
| Auditor ratification | Votes |
|---|
| For | 22,438,370 |
| Against | 1,145 |
| Abstentions | 1,581 |
| Broker non-votes | None |
Financial metrics, outlook, and risks
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, operating outlook, contingencies, or other financial metrics. It also does not disclose material changes versus a prior comparable period or unusual financial items.
Important facts for investors to verify
- Confirm the elected directors’ terms and any subsequent changes to board composition.
- Verify KPMG LLP’s appointment for the fiscal year ending December 31, 2022.
- Review the company’s periodic reports for financial performance, cash runway, financing needs, clinical-program updates, and risk factors not addressed in this Form 8-K.
